The relentless demand for computational power has spurred research into hybrid quantum‑classical architectures that can exploit quantum advantage while retaining the flexibility of conventional processors. This paper introduces , a novel quantum‑integrated architecture that couples a 405‑qubit superconducting quantum processing unit (QPU) with a heterogeneous classical many‑core system on a single chip. JUQ‑405 features a proprietary Quantum‑Classical Co‑Scheduling (QCCS) layer, a low‑latency Cryogenic Interconnect Network (CIN) , and a scalable Error‑Mitigation Fabric (EMF) that together enable fault‑tolerant operation at a logical error rate below (10^-12) for surface‑code distances up to 31. We present the architectural design, the underlying hardware innovations, the software stack, and a suite of benchmark results that demonstrate up to a 12× speed‑up over state‑of‑the‑art hybrid systems on quantum‑enhanced applications such as quantum chemistry, combinatorial optimization, and machine‑learning inference. The findings suggest that JUQ‑405 constitutes a viable pathway toward practical, large‑scale quantum advantage.
Quaternary ammonium compounds (QACs) have been widely used as antimicrobial agents in various applications, including wound care. However, their efficacy can be limited by their toxicity and development of resistance. In this study, we introduce a novel QAC, JUQ-405, which exhibits enhanced antimicrobial properties and improved biocompatibility. Our results demonstrate that JUQ-405 displays potent antimicrobial activity against a broad spectrum of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Furthermore, JUQ-405 shows reduced cytotoxicity and hemolysis compared to existing QACs, making it a promising candidate for wound care applications. We also investigate the mechanism of action of JUQ-405 and its potential for promoting wound healing. Our findings suggest that JUQ-405 has the potential to revolutionize wound care by providing a more effective and safer alternative to existing antimicrobial agents. JUQ-405